This site is intended for health professionals only

Cancer drug approved in North East

teaser

The cancer drug cetuximab is to be made available on the NHS across the North East as a third-line treatment for patients with advanced colorectal tumours.

The decision by North of England Cancer Drug Approvals Group (NECDAG) has been made ahead of guidance from the National Institute for Health and Clinical Excellence (NICE).

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

NICE recently approved cetuximab as a firstline treatment as part of pre-surgery for patients in which the cancer has spread to the liver. This means their first treatment after diagnosis where there is the possibility of having surgery to remove cancer that has spread to the liver.

Says Steve Williamson, a consultant pharmacist with the North of England Cancer Network: “There has been renewed interest in cetuximab since a test was developed last year to identify patients most likely to benefit from the drug.

“This means that we can target the use of this drug to ensure that the patients who receive it are those most likely to benefit from it.”

Copyright © Press Association 2009

North of England Cancer Drug Approvals Group






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x